◈ Nootpedia
Compact view
Research pass: thorough Supplement · Powder OPTIONAL-ADD HIGH

L-Tyrosine

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict OPTIONAL-ADD HIGH

A-tier evidence for stress-condition cognitive rescue (military training, cold, sleep deprivation) and B-tier for sustained working-memory under cognitive load — but no meaningful effect at baseline in non-depleted neurons. For Dylan-archetype, valid as PRN tool pre-sparring / pre-cognitive-load-day / pre-modafinil-washout-day; not a daily-core candidate. Cheap and safe. Verdict would upgrade to STRONG-CANDIDATE if Dylan moves to chronically sleep-deprived training blocks or if 23andMe shows COMT Val/Val (faster DA clearance, plausibly more responsive to substrate loading); would downgrade to SKIP-FOR-NOW only if subjective signal stays absent across ≥3 stressor exposures.

Research pass: thorough
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)
    OPTIONAL-ADD

    PRN tier. Pre-sparring days (Saturday hard-spar), pre-heavy-cognitive-load days, pre-modafinil-washout days. Not daily-core. Cheap insurance against catecholamine depletion in conditions where it actually exists. Stack-safe with V4/V5. Verdict: keep available, use 4-8×/month max.

  • 30-50, executive maintenance
    OPTIONAL-ADD

    Same PRN pattern — pre-presentation, pre-flight, pre-tax-deadline kind of usage. Daily use still not warranted unless someone is in chronically stress-loaded role.

  • 50+, mild cognitive decline
    CAUTION

    Older adults show altered tyrosine pharmacokinetics (van de Rest, Hase) — same dose produces higher plasma tyrosine. BP risks slightly elevated. The Eglin 2019 cold-exposure data is encouraging in this demographic but not a basis for daily nootropic use. PRN only with BP monitoring.

  • Anxiety-prone
    CAUTION

    Tyrosine elevates catecholamines, which is anxiolytic when DA/NE are depleted but ANXIOGENIC when they aren't. Met/Met COMT + anxiety phenotype = avoid or start at 500 mg only.

  • High athletic load, tested status
    USABLE

    Not WADA-banned. PRN pre-competition under sleep-deprived/jet-lagged/cold conditions makes sense.

  • Sleep-disordered
    STRONG-CANDIDATE

    for the chronically sleep-deprived. Best-studied population for tyrosine benefit. Daily 1-2 g AM is defensible if sleep debt is structural (e.g., shift workers, military, new parents). Doesn't fix the sleep — but blunts cognitive consequences of sleep loss. NOT a substitute for sleep hygiene.

  • Recovery-focused (post-injury, post-illness)
    OPTIONAL

    Not a recovery tool per se; mechanism is cognitive-rescue not physical-recovery. PRN if cognitive output is needed during a recovery period.

  • Strength/anabolic-focused
    NEUTRAL

    Tyrosine has no anabolic effect; thyroid-hormone-precursor angle is theoretical. Not a strength tool.

▸ Subjective experience (deep)

Onset: 30-90 min on empty stomach. Most users feel nothing acute.

Under stress conditions (the only conditions where tyrosine is supposed to do something), reports converge on:

  • "Easier to push through" sustained mental work
  • Less of the "fatigue wall" hit during long cognitive sessions or sleep-deprived workdays
  • Cleaner focus during high-stakes events (exams, fights, presentations)
  • Mild reduction in stress-induced cognitive blanking

At baseline (the condition most users actually try it in), reports converge on:

  • "I felt nothing"
  • "Maybe a little focus, hard to tell from placebo"
  • Some users report mild headache or jaw tension at higher doses (1-3 g)

Distinct from stimulants: No euphoria, no jitters, no acute drive lift, no appetite suppression, no insomnia. If you take 2 g of tyrosine and feel a clear "kick," that's almost certainly placebo or expectation effect — the pharmacology doesn't support an acute felt response in non-depleted states.

Distinct from theanine: Theanine produces a recognizable mild calm-clarity within 30-60 min in most users. Tyrosine does not produce that. They are often stacked because they target different dimensions (theanine = downregulating sympathetic over-arousal; tyrosine = providing substrate for catecholamine drive when depleted).

Variability: Among the most response-variable nootropics. COMT Val/Val carriers with otherwise low DA tone and chronic stress exposure may notice it; COMT Met/Met carriers with high baseline DA tone may not — and may even feel slightly worse (irritable, anger-prone) at higher doses (Lehr 2014 anger-increase signal).

▸ Tolerance + cycling deep dive
  • Tolerance buildup: essentially none at PRN dosing. The mechanism is substrate-replenishment in a bottleneck that only appears under stress — there is no receptor that desensitizes.
  • Recommended cycle: PRN only. Daily use is wasteful, not dangerous.
  • Reset protocol: N/A.
▸ Stacking deep dive

Synergistic with

  • modafinil: Modafinil works partly through DA reuptake inhibition (and broader monoamine + glutamate effects). Tyrosine provides substrate for the catecholamines that modafinil prevents from being cleared. Anecdotally, the pair "smooths" the modafinil profile under stress conditions. Not a daily pairing — PRN tyrosine on hard cognitive-load days while on daily modafinil.
  • caffeine + theanine: Classic stress-rescue stack. Caffeine = adenosine antagonism + indirect catecholamine release; theanine = sympathetic dampening / alpha-wave promotion; tyrosine = substrate for what caffeine elicits. The sum works for hard cognitive days.
  • bupropion: Bupropion is a NDRI (NE + DA reuptake inhibitor). Combining with tyrosine is mechanistically additive — more substrate + better preservation of released catecholamines. Not a pairing Dylan currently has, but valid if bupropion enters the stack.
  • sulbutiamine: Sulbutiamine restores prefrontal-cortex DA function via different mechanism (B1 derivative); the pair has anecdotal asthenia-rescue overlap. Both PRN tier.
  • phenylpiracetam: Phenylpiracetam has dopaminergic/sympathomimetic activity; tyrosine substrate complements. Used by athletes pre-event in Russian protocols.
  • B6 (P5P): P5P is a cofactor for AADC (the enzyme that converts L-DOPA → DA) and for DBH (DA → NE). Adequate B6 status is a quiet prerequisite for tyrosine to actually convert to catecholamines. Most multivitamins or Dylan's V4 stack already cover this.
  • Iron + folate: Cofactors for tetrahydrobiopterin (BH4) regeneration. BH4 is required for TH activity. Iron deficiency is a hidden brake on tyrosine→DA conversion. Not a supplementation recommendation per se — flag bloodwork (ferritin) when Dylan does June panel.

Avoid stacking with

  • High-dose MAO inhibitors: classical MAOIs (phenelzine, tranylcypromine), Emsam 9-12 mg patch, selegiline >10 mg oral. Hypertensive crisis risk. Hard contraindication.
  • High-protein meals immediately before/after: LNAA competition crowds tyrosine off the LAT-1 transporter. If you're taking tyrosine for cognitive effect, separate from whey/meat by ≥2 hours.
  • High-dose phenylalanine: competes hardest at LAT-1. Some users like the "DLPA" (DL-phenylalanine) supplement; combining DLPA + tyrosine in the same dose largely cancels the brain delivery benefit.
  • Levodopa (PD treatment): competes at LAT-1 for BBB transport AND at AADC for conversion. Patients on levodopa should not supplement tyrosine.
  • Thyroid hormone replacement: theoretical-only interaction; no clinical data shows meaningful issue in euthyroid adults, but flag if Dylan ever ends up on levothyroxine.

Neutral / safe co-administration

  • All of Dylan's V4 stack: DHA, magtein, citicoline, NAC, PS, magnesium glycinate, curcumin, rhodiola, theanine, glycine, D3+K2, beta-alanine, vitamin C, creatine — none of these interact meaningfully with tyrosine pharmacokinetics or pharmacodynamics.
  • L-Tryptophan: technically competes at LAT-1, but Dylan dosing tryptophan pre-bed and tyrosine PRN AM means temporal separation removes the issue.
  • ALCAR, taurine, agmatine: no meaningful interaction.
▸ Drug interactions deep dive
  • MAOIs (all classes): see above — hypertensive risk
  • Levodopa / carbidopa-levodopa: competition at LAT-1 + AADC; avoid co-administration
  • Thyroid hormones (levothyroxine, liothyronine): theoretical only; flag if ever relevant
  • Sympathomimetic stimulants (amphetamines, methylphenidate): additive catecholamine effect; not contraindicated but could amplify stim side effects (BP, anxiety) if both at high dose
  • CYP enzymes: tyrosine itself is not a meaningful CYP substrate, inhibitor, or inducer. No CYP-based interactions.
  • Hormonal contraceptives: no known interaction.
▸ Pharmacogenomics

This is the most useful section once Dylan's 23andMe results land (~June 2026).

COMT (rs4680, Val158Met)

The most important tyrosine-relevant variant. COMT degrades catecholamines (DA, NE, EPI) in the synapse and intracellularly.

  • Val/Val (~25% of Caucasians): "fast COMT" — degrades DA up to 4× faster than Met/Met. Lower baseline prefrontal DA tone. More likely to benefit from substrate loading like tyrosine because their faster clearance creates a persistent demand pull on synthesis. Often described as "warriors" — better stress resilience but lower baseline DA-driven creativity/curiosity.
  • Val/Met (~50%): intermediate.
  • Met/Met (~25% of Caucasians): "slow COMT" — high baseline DA tone. Less likely to benefit from tyrosine, more likely to feel anxious/jittery/anger-prone at higher doses. The Lehr 2014 "anger under stress" finding is plausibly a Met/Met effect (paper did not stratify).

For Dylan: check COMT genotype when 23andMe results land. Val/Val → tyrosine more useful, can dose 1-2 g comfortably. Met/Met → start at 500 mg, watch for irritability, consider skipping entirely.

MAO-A (rs6323, MAOA-uVNTR)

MAO-A degrades NE, EPI, serotonin (and some DA). Variants affect baseline NE tone.

  • High-activity MAOA variants: faster NE clearance — analogous logic to COMT Val/Val (more substrate-pull, more responsive to tyrosine).
  • Low-activity MAOA variants: higher baseline NE — more risk of anxiety/agitation with high-dose tyrosine.

MAO-B

Less directly relevant for tyrosine response but interacts with selegiline tier choice (see selegiline file).

DBH (rs1611115, C-1021T)

DBH converts DA → NE. Variants affect the DA:NE ratio after tyrosine loading.

  • Low-activity DBH (T allele homozygote): less efficient DA→NE conversion → relatively more DA, less NE generated from tyrosine substrate. Subjective tilt: more "drive/motivation," less "alertness/sympathetic."
  • High-activity DBH: more NE generated → more sympathetic / alert response.

TH (tyrosine hydroxylase) variants

Less common, but rare hypofunctional TH variants would be expected to blunt tyrosine response (the bottleneck stays at the enzyme even with abundant substrate). Not commonly tested on consumer arrays.

CYP2B6, CYP3A4

Not relevant for tyrosine itself (not metabolized via CYP) but relevant for many co-administered nootropics.

Practical pharmacogenomic note

Tyrosine response is one of the cleaner cases where the catecholamine-gene profile (COMT + MAO-A + DBH composite) predicts subjective response with reasonable plausibility. Not deterministic, but worth checking.

▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
OTC NOW Foods L-Tyrosine 500 mg, 120 caps ~$10-15 high Reputable, USP-tested, widely available iHerb/Amazon. Default pick.
OTC Doublewood L-Tyrosine 500 mg, 120 caps ~$15-20 high Tested by 3rd-party labs; clean labels.
OTC BulkSupplements L-Tyrosine powder, 250-500 g ~$15-25 high Best $/gram at higher doses (>2 g/day). Powder dosing requires gram scale.
OTC NOW Foods NALT — N-Acetyl L-Tyrosine ~$20-30 high Not recommended — pays premium for inferior plasma tyrosine elevation.
OTC Jarrow / Source Naturals L-Tyrosine ~$10-20 high Comparable to NOW.

Monthly cost at PRN use (1-2 g, 2-4×/week): $5-10/month. Effectively negligible. Monthly cost at daily 1-2 g (not recommended for Dylan): $10-20/month.

For Dylan: NOW Foods L-Tyrosine 500 mg caps, 120-count from iHerb is the right default. Add to next iHerb order; one bottle lasts 2-4 months at PRN use.

▸ Biomarkers to track (deep)

Baseline (before starting)

  • Resting BP (sit, 5 min) — establish a baseline since tyrosine can nudge BP up
  • TSH, free T4, free T3 — Dylan's June 2026 panel will cover; thyroid baseline matters for any catecholamine-pathway intervention given tyrosine's role as T3/T4 precursor
  • Ferritin (iron stores → BH4 cofactor for TH) — Dylan's June panel
  • B12, folate — methylation cofactors for COMT clearance

During use (PRN)

  • Subjective: cognitive output on stressor day (vs comparable non-tyrosine stressor day)
  • Subjective: irritability / jaw tension / headache within 4 hr post-dose
  • HR / BP if Oura ring is used — check for sustained elevation

Genotype (one-time, when 23andMe lands)

  • COMT rs4680
  • MAOA-uVNTR or rs6323
  • DBH rs1611115
  • TH (if reported on consumer array; usually not)

Not needed

  • Plasma tyrosine — research-grade only, not clinically actionable
  • Urine catecholamines / VMA / HVA — not actionable for nootropic dosing
▸ Controversies / open debates Live debate

NALT vs L-tyrosine bioavailability

Status: marketing claim of NALT superiority is not supported by pharmacokinetic data. Multiple studies show NALT raises plasma free tyrosine far less than equimolar L-tyrosine. Despite this, NALT continues to sell at a premium and feature in many nootropic stacks. Resolution: use plain L-tyrosine. The handful of vendors still pushing NALT as "premium" are either trading on solubility marketing or legacy formulation logic from IV-nutrition contexts that doesn't transfer to oral.

Baseline vs stress-condition efficacy

Status: the strongest mechanistic interpretation (TH bottleneck only under high-firing conditions) implies tyrosine should produce minimal effect at baseline. Most baseline trials confirm this. Some users insist they "feel" tyrosine at baseline; the most parsimonious reading is placebo + occasional COMT Val/Val benefit + anchoring to mild physical sensations. Resolution: do not expect baseline benefit. Use PRN for actual stressors.

Anger / aggression under severe stress (Lehr et al., 2014)

Status: in a high-severity stress paradigm, tyrosine increased subjective anger ratings vs placebo. Replicated only weakly. Mechanistically plausible (more catecholamines = stronger sympathetic/aggression-flavor stress response). Resolution: flag it. For combat-sport athlete (Dylan), some stress-amplification of fight response is potentially desirable, not a problem; for office-stress users, this is a genuine downside to monitor.

"Tyrosine works for ADHD"

Status: persistent online claim; clinical evidence is thin and inconsistent. Some ADHD users self-report benefit; controlled trials have not shown reliable effect. Resolution: do not treat tyrosine as an ADHD therapy; if cognitive-output issues persist after PRN trial, evaluate stimulant or atomoxetine.

Dose ceiling

Status: human safety data exists up to ~12 g/day in research settings. Higher doses have no demonstrated benefit and increase BP/headache risks. Some online protocols recommend ≥150 mg/kg routinely; this is excessive for non-extreme-stress contexts. Resolution: 500 mg-2 g is the sane PRN range for cognitive contexts; reserve 100-150 mg/kg for actual extreme-stress paradigms (cold, severe sleep dep).

Daily continuous use risk?

Status: no evidence of toxicity or tolerance at 1-2 g/day chronic use. But also no evidence of benefit in non-stressed states, so daily use is mostly cost without payoff. Resolution: PRN beats daily on cost-benefit grounds.

Inverted-U dose response

Status: older-adult studies (Hase 2015, van de Rest 2017) suggest some cognitive measures show non-monotonic dose-response — better at moderate dose, worse at higher dose. Mechanism interpretation: too much catecholamine = too much sympathetic / cognitive over-arousal. Resolution: more is not better. Start at 500 mg-1 g; only escalate if no felt effect.

▸ Verdict change log
  • 2026-05-05 — Initial verdict: OPTIONAL-ADD, HIGH confidence. PRN tool for Dylan-archetype: pre-sparring, pre-heavy-cognitive-load, pre-modafinil-washout. Not daily-core. Cheap, safe, evidence-supported in stress conditions, null at baseline, NALT inferior to plain L-tyrosine.
▸ Open questions / gaps Open
  • Does tyrosine response correlate with COMT genotype in healthy young adults? Mechanistically expected but not directly tested in a stratified RCT. Once 23andMe lands, retrospective N-of-1 stratification is possible.
  • Does daily low-dose tyrosine (500 mg) under chronic mild stress (Dylan's 6-12 hr cognitive workload) produce different effects than acute PRN? Trial-quality data is missing. Anecdotally users converge on "no — PRN is the right shape."
  • What is the optimal pre-event timing window? Most studies use 30-90 min; 60 min on empty stomach is the modal pick. No fine-grained timing study exists.
  • NALT — is there ANY dose at which it equals plain L-tyrosine? Probably not at any reasonable oral dose; conversion efficiency caps the upside. No reason to keep researching.
  • Is there a tyrosine + BH4 (or sapropterin) synergy worth considering? Mechanistically plausible — BH4 is the TH cofactor — but sapropterin is an expensive Rx for PKU and not realistic for nootropic use. Folate + iron sufficiency does the same job through endogenous BH4 maintenance.
  • Combat-sport-specific evidence: zero direct studies. The closest analogues are military training cadet studies, which transfer reasonably given physical-stress + cognitive-decision-making overlap.
▸ Sources (full, with our context)
Back to compact view